Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

81. The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis Inplasy Protocol 319 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

82. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review (...) at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Original article Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of Prostate Cancer: A Systematic Review and Meta-Analysis Sungmin Woo, Soleen Ghafoor, Anton S. Becker, Sangwon Han

2020 Research Square

83. An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Guideline Endorsement 3-22 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline H. Lukka, J. Brown, C. Catton, B. Shayegan (...) and the Hypofractionated Radiation Therapy for Prostate Cancer Guideline Development Group Report Date: April 28, 2020 This publication is an OH (CCO) Hypofractionated Radiation Therapy for Prostate Guideline Development Group Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO and AUA Evidence-based Guideline. The original publication is available at: https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s- guideline

2020 Cancer Care Ontario

84. Faculty Opinions recommendation of The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. Full Text available with Trip Pro

Faculty Opinions recommendation of The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. The efficacy and safety of radical prostatectomy and... | Faculty Opinions On April 12th, 2020, F1000Prime became Faculty Opinions. See our to learn more. Welcome Guest 1 Recommendations info_outline Systematic Review / Meta-analysis New Finding close Classified As New Finding 1 Article Type Systematic Review / Meta-analysis (...) More more_vert close Download article Export article Sciwheel Download citation BibTeX RIS Share Email The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. ARTICLE PUBLISHED: 2020 Feb 24 CITE AS: World J Surg Oncol. 2020 Feb 24 ; 18 ( 1 ): 42 Recommendations Abstract Comments You have reached your article limit. Register for 30-day free trial Registration is free and only takes a moment, or subscribe for unlimited

2020 Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

85. Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer? a protocol of systematic review and meta-analysis Full Text available with Trip Pro

Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer? a protocol of systematic review and meta-analysis Inplasy Protocol 134 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

86. Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: a protocol of systematic review and meta-analysis Full Text available with Trip Pro

Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: a protocol of systematic review and meta-analysis Inplasy Protocol 98 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

87. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. (Abstract)

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management.In this multicentre, two-arm (...) , randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant metastases were identified. The primary outcome was accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease

2020 Lancet

88. Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis | medRxiv Search for this keyword Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysis Keyvan Heydari , Sahar Rismantab , Amir Shamshirian , Pouya Houshmand , Parisa Lotfi , Sajjad Rafati , Amir Aref , Ali Saravi , Danial Shamshirian , Behdad (...) , School of Medicine, Gonabad University of Medical Sciences , Gonabad, Iran Reza Alizadeh-Navaei 2 Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences , Sari, Iran For correspondence: Abstract IMPORTANCE Prostate cancer (PC) is the second most common cancer among males globally, however, the survival rate is favorable in most patients. In a small number of patients, who suffer from advanced or invasive cancer, various side effects such as secondary malignancies

2020 Cold Spring Harbor Laboratory

89. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Full Text available with Trip Pro

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy (...) results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Eur Urol Actions . 2020 Feb 21;S0302-2838(20)30115-9. doi: 10.1016/j.eururo.2020.02.009. Online ahead of print. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

90. The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial Full Text available with Trip Pro

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial The Effect of Assessing Genetic Risk of Prostate Cancer on the Use of PSA Tests in Primary Care: A Cluster Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation PLoS Med Actions . 2020 Feb 7;17(2):e1003033. doi: 10.1371/journal.pmed.1003033. eCollection 2020 Feb. The Effect of Assessing Genetic Risk of Prostate Cancer on the Use of PSA Tests in Primary Care: A Cluster Randomized Controlled Trial , , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 2 Department of Molecular Medicine, Aarhus

2020 EvidenceUpdates

91. Darolutamide (Nubeqa) - prostate cancer

Darolutamide (Nubeqa) - prostate cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/58296/2020 EMEA/H/C/004790 Nubeqa (darolutamide) An overview of Nubeqa and why (...) it is authorised in the EU What is Nubeqa and what is it used for? Nubeqa is a medicine used to treat men with prostate cancer. It is used when the cancer is castration-resistant (worsens despite treatment to lower testosterone levels, including surgical removal of the testes) and is at high risk of metastasis (spreading to other parts of the body). Nubeqa contains the active substance darolutamide. How is Nubeqa used? Nubeqa is available as tablets (300 mg) and can only be obtained with a prescription

2020 European Medicines Agency - EPARs

92. Discrimination between clinical significant and insignificant prostate cancer with Apparent diffusion coefficient – A systematic review and meta analysis Full Text available with Trip Pro

Discrimination between clinical significant and insignificant prostate cancer with Apparent diffusion coefficient – A systematic review and meta analysis Discrimination between clinical significant and insignificant prostate cancer with Apparent diffusion coefficient – A systematic review and meta analysis | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC Cancer . A preprint is a preliminary version of a manuscript that has not completed peer review (...) at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Discrimination between clinical significant and insignificant prostate cancer with Apparent diffusion coefficient – A systematic review and meta analysis Hans-Jonas Meyer, Andreas Wienke, Alexey Surov Hans-Jonas

2020 Research Square

93. Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Full Text available with Trip Pro

Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal (...) . Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Zhong-yu Gao, Tao Zhang, Hui Zhang, Cheng-gang Pang, Wen-xue Jiang Zhong-yu Gao

2020 Research Square

94. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. Full Text available with Trip Pro

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. The use of 12-core systematic prostate biopsy is associated with diagnostic inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer. Biopsies performed with magnetic resonance imaging (MRI) targeting may reduce the misclassification of prostate cancer in men with MRI-visible lesions.Men with MRI-visible prostate lesions underwent both MRI-targeted and systematic biopsy. The primary (...) was associated with the fewest upgrades to grade group 3 or higher on histopathological analysis of surgical specimens (3.5%), as compared with MRI-targeted biopsy (8.7%) and systematic biopsy (16.8%).Among patients with MRI-visible lesions, combined biopsy led to more detection of all prostate cancers. However, MRI-targeted biopsy alone underestimated the histologic grade of some tumors. After radical prostatectomy, upgrades to grade group 3 or higher on histopathological analysis were substantially lower

2020 NEJM

95. Identification of potential biomarkers associated with pathogenesis of primary prostate cancer based on meta-analysis approaches Full Text available with Trip Pro

Identification of potential biomarkers associated with pathogenesis of primary prostate cancer based on meta-analysis approaches Identification of potential biomarkers associated with pathogenesis of primary prostate cancer based on meta-analysis approaches | bioRxiv Search for this keyword New Results Identification of potential biomarkers associated with pathogenesis of primary prostate cancer based on meta-analysis approaches Neda Sepahi , Mehrdad Piran , Mehran Piran , Ali Ghanbariasad doi (...) of Medical Sciences , Fasa, Iran 3 Bioinformatics and Computational Biology Research Center, Shiraz University of Medical Sciences , Shiraz, Iran Ali Ghanbariasad 1 Department of Medical Biotechnology, Fasa University of Medical Sciences , Fasa, Iran 2 Noncommunicable Diseases Research Center, Fasa University of medical sciences , Fasa, Iran For correspondence: Abstract Worldwide prostate cancer (PCa) is recognized as the second most common diagnosed cancer and the fifth leading cause of cancer death

2020 Cold Spring Harbor Laboratory

96. Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer

Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer 1 Public Summary Document Application No. 1525 - Low dose-rate (LDR) brachytherapy for intermediate and high-risk prostate cancer Applicant: BXTAccelyon Australia Pty Ltd Date of MSAC consideration: MSAC 76 th Meeting, 1-2 August 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefits (...) Schedule (MBS) listing of LDR Brachytherapy (LDR-BT) for intermediate and high-risk prostate cancer was received from MedTechnique on behalf of BXTAccelyon Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support public funding for LDR- BT boost (following primary external beam radiotherapy [EBRT]) for intermediate

2020 Medical Services Advisory Committee

97. Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial Full Text available with Trip Pro

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing of these therapies is unclear. Our phase III trial compared neoadjuvant versus concurrent initiation of ADT in combination with dose-escalated prostate RT (PRT).Patients with newly (...) diagnosed LPCa with Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated to neoadjuvant and concurrent ADT for 6 months starting 4 months before RT (neoadjuvant group) or concurrent and adjuvant ADT for 6 months starting simultaneously with RT (concurrent group). The primary end point was biochemical relapse-free survival (bRFS). Stratified log-rank test was used to compare bRFS and overall survival (OS). Incidence of grade ≥ 3 late RT-related

2020 EvidenceUpdates

98. Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and meta‐analysis Full Text available with Trip Pro

Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and meta‐analysis Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and meta‐analysis - Zheng - 2020 - Precision Medical Sciences - Wiley Online Library Working off-campus? Learn about our By continuing to browse this site, you agree to its use of cookies as described in our . Search (...) within Search term Search term ORIGINAL ARTICLE Open Access Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and meta‐analysis Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, 210009 China Department of Radiology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University

2020 Precision Medical Sciences

99. Coffee consumption is associated with a lower risk of prostate cancer: a meta-analysis Full Text available with Trip Pro

Coffee consumption is associated with a lower risk of prostate cancer: a meta-analysis Coffee consumption is associated with a lower risk of prostate cancer: a meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its (...) validity or suitability for dissemination as established information or for guiding clinical practice. Research Coffee consumption is associated with a lower risk of prostate cancer: a meta-analysis Xiaonan Chen, Yiqiao Zhao, Zijia Tao, Kefeng Wang Xiaonan Chen Shengjing Hospital of China Medical University Yiqiao Zhao Shengjing Hospital of China Medical University Zijia Tao Shengjing Hospital of China Medical University Kefeng Wang Shengjing Hospital of China Medical University Corresponding Author

2020 Research Square

100. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Full Text available with Trip Pro

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy.In this multicentre, randomised, open-label, phase 2, crossover (...) trial done in six cancer centres in British Columbia, Canada, we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation and Eastern Cooperative Oncology Group performance status 2 or less. Patients were randomly assigned (1:1) using a computer-generated random number table to receive either abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed

2020 EvidenceUpdates